Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 23 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
NEXT GEN PHARMA from Zottegem, company number BE0794344975, closed financial year 2025 with a result of € 611,794 after tax. For that financial year NEXT GEN PHARMA recorded a gross margin of € 75,736 and equity of € 3.2 million. Compared with financial year 2024, the result moved from € 691,805 to € 611,794. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 7, 2026.
€ 3.2 million
▲ 24% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 611,794
▼ 12% vs 2024
Profit after tax over the fiscal year.
€ 76,134
▼ 74% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 1.8 million.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
€ 12,344
▲ 8% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 2.9 million
▼ 24% vs 2024
€ 428,571 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.
€ 16,526
▲ 67% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 91,724
▲ € 72,332 vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € 147,959 | € 110,615 | € 75,736 | ▼ 32% |
| Profit after taxes | € 508,395 | € 691,805 | € 611,794 | ▼ 12% |
| Equity | € 1,882,395 | € 2,574,200 | € 3,185,994 | ▲ 24% |
| Total debts | € 4,249,765 | € 3,823,422 | € 2,995,631 | ▼ 22% |
| Cash | € 37,964 | € 292,890 | € 76,134 | ▼ 74% |
| Retained profit | € 508,395 | € 1,200,200 | € 1,811,994 | ▲ 51% |
| Bank debt | € 4,197,429 | € 3,768,857 | € 2,865,286 | ▼ 24% |
| Balance sheet total | € 6,132,160 | € 6,397,622 | € 6,181,625 | ▼ 3% |
Key figures of NEXT GEN PHARMA, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to NEXT GEN PHARMA?
What happened at NEXT GEN PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 611,794 (▼ 12% vs 2024). filed late Source: NBB ↗
- New establishment in Zottegem. KBO
- Jeremy Coessens became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 508,395 profit in 2023 to € 611,794 profit in 2025.
Paid € 75,477 in corporate taxes since 2023.
Best year ever: 2024, with € 691,805 profit.
A new publication or filing at NEXT GEN PHARMA? We notify you, reason included.
Follow NEXT GEN PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind NEXT GEN PHARMA is Jeremy Coessens. The shares are held by Jeremy Coessens.
Establishments
Establishment units
Physical locations of this company
Laurens De Metsstraat 72D box 6
9620 Zottegem
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0794.344.975
- VAT number
- BE 0794.344.975
- Registered office
- Laurens De Metsstraat 72D bus 6, 9620 Zottegem
- Names & denominations
- NEXT GEN PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 2 December 2022
- Peppol
- Active · Active since 2 Dec 2025
- Activities · NACE
Activiteiten van holdings
Holdings
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige zakelijke dienstverlening, neg
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering